



Access and Global Health

Viatriis works to be a model for sustainable access to medicine at scale and a reliable partner in addressing some of the world’s most enduring health challenges. We do this through our extensive and diverse portfolio of medicines, addressing nearly every health need, a one-of-a-kind global supply chain designed to reach more people with health solutions when and where they experience need, and by leveraging our deep scientific expertise.

As part of promoting sustainable access to medicines and supporting more resilient healthcare systems, we have set companywide goals to provide access to antiretrovirals for adults and children living with HIV and to promote healthcare professional education (HCP) and outreach.

Supplied high-quality medicines to ~1B patients around the world¹

>250 products on the WHO Essential Medicines List (EML) and >150 medicines in the WHO EML for Children

Provided products that address the top 10 of the WHO’s leading causes of death globally


Sold >80 billion doses of Medicine across >165 countries and territories

Supplied medicines to >90% of low- and lower-middle-income countries

59 products on the WHO Prequalification of Medicines List

Building Access Through a Global and Flexible Supply Chain

Access to medicines depends on reliable supply and availability of medicines - the right medicine, in the right place, at the right time. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, when they need them. No country can make every medicine people need, and no medicine is made in every country. A secure supply of medicines from multiple regions and countries around the world is more reliable and at less risk of being disrupted. Global, diverse and flexible supply chains are key to timely and affordable access to medicine.

 [Learn how a global supply chain connects people with medicines.](#)

As an essential business, Viatriis has taken actions to maintain a reliable supply of medicines, with special measures around critical medicines in times of volatile demand. Our ability to supply medicines and maintain high levels of service around the world is rooted in our global network of suppliers with a robust ability to manage shocks affecting any particular country or region. Our network allows us to offset risk and build resilience. In 2023, we were able to maintain a global customer service level of 90% on time in full amid volatility in demand, inflation and supply chain disruptions in general.

All Viatriis operations are covered by and expected to comply with statutory and regulatory requirements, such as current Good Manufacturing Practices (cGMP), Good Pharmacovigilance Practices (GPvP), Good Distribution Practices (GDP) and Good Clinical Practices (GCP) for all markets that they serve.

Addressing the Global Burden of NCDs

In 2023, noncommunicable diseases (NCDs) continued to dominate as the leading causes of death globally according to WHO, accounting annually for about 74% of all deaths. We offer an extensive portfolio of medicines to address nearly every health need. Notable treatments were launched or received regulatory approval in 2023 in the areas of cardiovascular and respiratory health as well as dermatology and ophthalmology.

Of the approximately 41 million NCD deaths annually, 77% occur in lower- and middle-income countries, adding to the dual burden of NCD and infectious disease. NCDs representing significant burdens of disease include heart disease, cancer, respiratory diseases, diabetes and mental health disorders.

Goal: Impact 100 million patients via HCP education and outreach regarding prevention, diagnosis and treatment options for cardiovascular disease, diabetes, cancer and other important chronic conditions to improve outcomes through the NCD Academy by the end of 2025.*

Our Progress: More than 24,000 individuals have an NCD Academy account, representing approximately 60.5 million patients impact to date.²

*Our ability to make progress on our goals depends on several factors, some of which are outside of our control.

Continued Innovation for Infectious Disease

Increased availability of testing and medicines has led to global progress in preventing and managing infectious diseases like HIV, tuberculosis (TB), malaria and hepatitis in the last quarter of a century. However, progress is slower in some low- and lower-middle-income countries where the needs are greatest, especially among more vulnerable groups like women and children. In addition, the COVID-19 pandemic, continuing emergence of antimicrobial resistance (AMR) and growing impacts from climate change have demonstrated how infectious threats can emerge and have devastating global effects.

At Viatris, we have expanded access at scale to high-quality HIV/AIDS treatment for more than a decade. Our work includes helping to prevent HIV infections, increasing diagnosis and treatment and providing healthcare solutions. Viatris files all relevant ARV products based on country guidelines across key high-burden HIV countries.

- Viatris has more than **700 registrations of infectious disease products** across LMICs.
- Viatris provides access to **high-quality and affordable ARVs in ~125 countries**.
- Viatris has **>45% of the anti-infective medicines** in the Essential Medicines List for Children.
- **~32% of people on treatment for HIV** use a Viatris product.³
- **~65% of children on treatment for HIV** use a Viatris product.³

Goal: Provide ARV therapy equivalent to a total of 30 million patients, including more than 2 million children living with HIV/AIDS, between 2022 and the end of 2025.*

Our Progress: In 2023, we provided treatments for approximately 8.6 million patients, including more than 670,000 children living with HIV/AIDS. Since 2022, we have provided treatments for nearly 17 million adults and children.

*Our ability to make progress on our goals depends on several factors, some of which are outside of our control.

AMR: A Major Global Health Risk

AMR is recognized around the world as a significant threat to global health and economic development. It is a major driver of death globally. By 2050, it is estimated that AMR will cause more deaths than cancer unless concerted efforts are undertaken to counter its progression.

Access to a wide array of high-quality antimicrobials and timely treatment are key in mitigating the rise of AMR. Viatris recently launched a treatment for multi-drug resistant TB (MDR-TB), only the third new anti-TB drug approved in the past half-century.

As a founding member of the AMR Industry Alliance, we are committed to partnering across the industry to collectively advance initiatives addressing AMR.

Viatris' Relevant Portfolio in the Fight on AMR

- Approximately 90 antimicrobials in our global portfolio
- More than 50% of the anti-infective medicines on the WHO EML
- 100% of medicines in 10 of the Essential Medicines List's Anti-Microbials Subsections
- 100% of medicines in seven of the Essential Medicines List for Children Anti-Microbials Subsections

Breaking Down Systemic Barriers to Access through Policy Engagement

We leverage our global experiences, scientific expertise and operations knowledge to support policymakers in identifying policies that advance access to quality medicines and build systems that sustain availability while minimizing unintended consequences.

Given the breadth of our portfolio and geographic footprint, Viatris is well positioned to support policymakers in identifying opportunities for policy change aligned with advancing access to medicines – not just for one medicine, or one disease, but for all medicines. Taking a systems-level approach to consider policy enablers of access allows us to identify the changes that could facilitate access, not only for one company, but for all seeking to serve the world's health needs.

For more information, read the [Viatris 2023 Sustainability Report](#).

¹The number of patients served is an estimate calculated using internal sales data (global volume of doses sold in 2023 in all markets as aligned with IQVIA standard units), divided by estimated per patient usage, which is based on treatment dose, treatment duration, and treatment adherence as estimated by Viatris Medical Affairs based on approved label indication and instructions for use, current international guideline recommendations, and common usage in clinical practice. Patients using multiple Viatris medicines may be counted as multiple patients. Certain adjustments were applied in consideration of completed and pending divestitures and to account for acceptable alternatives to the patient usage factors noted above, and rounded to the nearest hundred million. Estimates may be subject to reassessment.

² Patient reach calculated by multiplying the number of HCP learners by the average number of patients treated, as self-reported by HCP learners upon registering for NCD Academy. Patient reach includes unique patients as well as repeat patient encounters.

³ Excludes the U.S., EU and other developed markets. Also excludes Russia, China and Mexico, where we do not commercialize ARVs.



Viatri.com



LinkedIn



@ViatrisInc



@ViatrisInc



YouTube



Listen Well Podcast